Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Zoetis Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF and Zoetis Inc are close in size by market cap, and Zoetis Inc pays a 2.9% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Zoetis Inc for 70 Days on average.
| LQD | ZTS | |
|---|---|---|
Market Cap | $28.50B | $30.20B |
Volume | 37,320,110 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $147.53 |
52-Week Low | $101.83 | $69.09 |
Typical Hold Time | 125 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September 2026 and concerns about rising Treasury yields impacting investment-grade corporate bonds.
The outlook remains cautious as rising interest rates pressure bond ETFs, though LQD's 4.8% yield and high-quality portfolio provide some stability. Key risks include further bond market volatility and economic uncertainty, while institutional activity shows mixed sentiment with elevated short positions.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
